Retention in naltrexone implant treatment for opioid dependence

Drug and Alcohol Dependence

Volumn 111, Issue 1-2, 2010, Pages 166-169

  Kunøe, Nikolaj ^a   Lobmaier, Philipp ^a   Vederhus, John Kåre ^b   Hjerkinn, Bjørg ^b   Hegstad, Solfrid ^c   Gossop, Michael ^d   Kristensen, Øistein ^b   Waal, Helge ^a  

^a Norwegian Centre for Addiction Research   (Norway)

^b SØRLANDET HOSPITAL   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Heroin; Naltrexone; Naltrexone implant; Opioids; Retention; Sustained release

Indexed keywords

DIAMORPHINE; NALTREXONE;

ADULT; ARTICLE; BLOOD SAMPLING; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG IMPLANT; DRUG RELEASE; DRUG USE; FEMALE; HAIR ANALYSIS; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REIMPLANTATION; SOCIAL PROBLEM; SUSTAINED DRUG RELEASE;

ADULT; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PATIENT DROPOUTS; TREATMENT OUTCOME;

EID: 77956190883     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.03.021     Document Type: Article

References (36)

1. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 1961, 4:561-571.
2. Carroll K.M., Ball S.A., Nich C., O'Connor P.G., Eagan D.A., Frankforter T.L., Triffleman E.G., Shi J., Rounsaville B.J. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: effi{ligature}cacy of contingency management and signifi{ligature}cant other involvement. Arch. Gen. Psychiatry 2001, 58:755-761.
3. Comer S.D., Collins E.D., Kleber H.D., Nuwayser E.S., Kerrigan J.H., Fischman M.W. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl). 2002, 159:351-360.
4. Comer S.D., Sullivan M.A., Yu E., Rothenberg J.L., Kleber H.D., Kampman K., Dackis C., O'Brien C.P. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2006, 63:210-218.
5. Derogatis L.R., Lipman R.S., Rickels K., Uhlenhuth E.H., Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav. Sci. 1974, 19:1-15.
6. Fram D.H., Marmo J., Holden R. Naltrexone treatment-the problem of patient acceptance. J. Subst. Abuse Treat. 1989, 6:119-122.
7. Greenstein R.A., Evans B.D., McLellan A.T., O'Brien C.P. Predictors of favorable outcome following naltrexone treatment. Drug Alcohol Depend. 1983, 12:173-180.
8. Greenstein R.A., Fulada P.J., O'Brien C.P. Alternative pharmacotherapies for opiate addiction. A Comprehensive Textbook of Substance Abuse 1997, 415-425. Williams and Wilkins, New York. 3rd ed. J.H. Lowinson, P. Ruiz, R.B. Millman, J.G. Langrod (Eds.).
9. Hegstad S., Khiabani H.Z., Kristoffersen L.N., Kunøe N., Lobmaier P.P., Christophersen A.S. Drug screening of hair by liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 2008, 32:364-372.
10. Hulse G.K., Arnold-Reed D.E., O'Neil G., Chan C.T., Hansson R., O'Neil P. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict. Biol. 2004, 9:59-65.
11. Hulse G.K., Arnold-Reed D.E., O'Neil G., Chan C.T., Hansson R. Achieving long-term continuous blood naltrexone and 6-beta coverage following sequential naltrexone implants. Addict. Biol. 2004, 9:67-72.
12. Hulse G.K., Tait R.J., Comer S.D., Sullivan M.A., Jacobs I.G., Arnold-Reed D.E. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend. 2005, 79:351-357.
13. Hulse G.K., Morris N., Arnold-Reed D.E., Tait R.J. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch. Gen. Psychiatry 2009, 66:1108-1115.
14. Kokkevi A., Hartgers C. EUROPASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur. Addict. Res. 1995, 1:208-210.
15. Krupitsky E.M., Zvartau E.E., Masalov D.V., Tsoi M.V., Burakov A.M., Egorova V.Y., Didenko T.Y., Romanova T.N., Ivanova E.B., Bespalov A.Y., Verbitskaya E.V., Neznanov N.G., Grinenko A.Y., O'Brien C.P., Woody G.E. Naltrexone for heroin dependence in St. Petersburg, Russia. J. Subst. Abuse Treat. 2004, 26:285-294.
16. Kunøe N., Lobmaier P., Vederhus J.K., Hjerkinn B., Hegstad S., Gossop M., Kristensen Ø., Waal H. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Brit. J. Psychiatry 2009, 194:541-546.
17. Lobmaier P., Kunøe N., Gossop M., Katevoll T., Waal H. Naltrexone implants compared to methadone: outcomes 6 months after prison release. Eur. Addict. Res. 2010, 16:139-145.
18. Martin W.R., Jasinski D.R., Mansky P.A. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch. Gen. Psychiatry 1973, 28:784-791.
19. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., Argeriou M. The Fifth Edition of the Addiction Severity Index. J. Subst. Abuse Treat. 1992, 9:199-213.
20. Minozzi S., Amato L., Vecchi S., Davoli M., Kirchmayer U., Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst. Rev. 2006, (Art. No.: CD001333). 10.1002/14651858.
21. Ngo H.T., Arnold-Reed D.E., Hansson R.C., Tait R.J., Hulse G.K. Blood naltrexone levels over time following naltrexone implant. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:23-28.
22. Nunes E.V., Rothenberg J.L., Sullivan M.A., Carpenter K.M., Kleber H.D. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?. Am. J. Drug Alcohol Abuse 2006, 32:503-517.
23. Olsen L., Christophersen A.S., Frogopsahl G., Waal H., Mørland J. Plasma concentrations during naltrexone implant treatment of opiate-dependent patients. Br. J. Clin. Pharmacol. 2004, 58:219-222.
24. Pavot W., Diener E., Suh E. The temporal satisfaction with life scale. J. Pers. Assess. 1998, 70:340-354.
25. Resnick R.B., Volavka J., Freedman A.M., Thomas M. Studies of EN-1639A (naltrexone): a new narcotic antagonist. Am. J. Psychiatry 1974, 131:646-650.
26. Rothenberg J.L., Sullivan M.A., Church S.H., Seracini A., Collins E., Kleber H.D., Nunes E.V. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J. Subst. Abuse Treat. 2002, 23:351-360.
27. Ross J., Teesson M., Darke S., Lynskey M., Ali R., Ritter A., Cooke R. The characteristics of heroin users entering treatment: fi{ligature}ndings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005, 24:411-418.
28. San L., Pomarol G., Peri J.M., Olle J.M., Cami J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br. J. Addict. 1991, 983-990.
29. Sobell L.C., Sobell M.B. Timeline follow-back: a technique for assessing self-reported alcohol consumption. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods 1992, 41-72. Humana Press, Totowa, NJ. R.Z. Litten, J.P. Allen (Eds.).
30. Sullivan M.A., Vosburg S.K., Comer S.D. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacolgy (Berl). 2006, 189:37-46.
31. Sullivan M.A., Rothenberg J.L., Vosburg S.K., Church S.H., Feldman S.J., Epstein E.M., Kleber H.D., Nunes E.V. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am. J. Addict. 2006, 15:150-159.
32. Tait R.J., Ngo H.T., Hulse G.K. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J. Subst. Abuse Treat. 2008, 35:116-124.
33. Timko C., DeBenedetti A. A randomized controlled trial of intensive referral to 12-step self-help groups: one-year outcomes. Drug Alcohol Depend. 2008, 90:270-279.
34. Tukey J.W. Exploratory Data Analysis 1977, Addison-Wesley, Reading, MA.
35. Verebey K., Volavka J., Mulé S.J., Resnick R.B. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin. Pharmacol. Ther. 1976, 20:315-328.
36. Waal H., Frogopsahl G., Olsen L., Christophersen A.S., Mørland J. Naltrexone implants-duration, tolerability and clinical usefulness. A pilot study. Eur. Addict. Res. 2006, 12:138-144.